{
    "nct_id": "NCT03495427",
    "official_title": "The Utility of PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men With High GC Decipher® Test Scores: A Sub-aim of the VANDAAM Study (MCC #18523)",
    "inclusion_criteria": "* This study will enroll 60 patients previously enrolled to MCC#18523, \"A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African-American and Non-African American Men with Prostate Cancer: (VANDAAM)\" that had high risk Decipher test results (Decipher score >0.45).\n* Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1\n* Previously enrolled to MCC#18523\n* Genomic Classifier (GC) testing successfully completed on biopsy and/or surgical specimen\n* Decipher score from participation on the MCC#18523 study meets the criteria for high-risk (>0.45)\n* Treated with radical prostatectomy (RP) or radiation therapy (RT) (+/- short-term androgen deprivation therapy (ADT)) with ≥2 years follow up\n* Age > 18\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* No follow up information available post treatment\n* Unable to undergo PET imaging due to pre-existing comorbidities and/or claustrophobia\n* Administration of any radioisotope within 5 physical half-lives OR any IV X-ray contrast medium within 24 hours OR any high-density oral contrast medium (oral water contrast acceptable) within 5 days prior to study drug injection",
    "miscellaneous_criteria": ""
}